SCHEMBL734564

SCHEMBL734564

CC1C(=O)N(CCC=O)CCN1c1cccc(OC(F)(F)F)c1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 4/20 0.45
DRD3 P35462 4/20 0.45
KCNH2 Q12809 4/20 0.45
NOTUM Q6P988 1/20 0.39
HCRTR1 O43613 6/20 0.38
HCRTR2 O43614 6/20 0.38
MCHR1 Q99705 1/20 0.37
CARM1 Q86X55 2/20 0.37
PRMT6 Q96LA8 2/20 0.37
FFAR4 Q5NUL3 1/20 0.37
ROCK2 O75116 1/20 0.36
ROCK1 Q13464 1/20 0.36
PIM1 P11309 1/20 0.35
CHRM2 P08172 1/20 0.35
CHRM1 P11229 1/20 0.35
CHRM3 P20309 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL756909 0.82 DRD2 (0.47) DRD2DRD3KCNH2HRH3
SCHEMBL734557 0.82 DRD2 (0.47) DRD2DRD3KCNH2HRH3
SCHEMBL734556 0.82 DRD2 (0.47) DRD2DRD3KCNH2HRH3
SCHEMBL735891 0.82 DRD2 (0.47) DRD2DRD3KCNH2HRH3
SCHEMBL733503 0.79 DRD2 (0.40) DRD2DRD3KCNH2NOTUMHCRTR1
SCHEMBL27812001 0.78 NOTUM (0.43) DRD2DRD3KCNH2NOTUMHCRTR1
SCHEMBL27832141 0.77 NOTUM (0.42) DRD2DRD3KCNH2NOTUMHCRTR1
SCHEMBL734391 0.76 DRD2 (0.40) DRD2DRD3KCNH2NOTUMHCRTR1
SCHEMBL735583 0.76 DRD2 (0.40) DRD2DRD3KCNH2NOTUMHCRTR1
SCHEMBL735042 0.76 DRD2 (0.40) DRD2DRD3KCNH2NOTUMHCRTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102112451-B Diazepan and piperazine derivatives modulators of chemokine receptors HOFFMANN LA ROCHE 2014-01-22 CN disclosed
US-8138175-B2 Heterocyclyl compounds HOFFMANN-LA ROCHE INC. (US) 2012-03-20 US disclosed
CN-102112451-A Diazepan and piperazine derivatives modulators of chemokine receptors HOFFMANN LA ROCHE 2011-06-29 CN disclosed
EP-2321285-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. Hoffmann-La Roche AG (CH) 2011-05-18 EP disclosed
WO-2010012619-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2010-02-04 WO disclosed
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS CCR2, CCR3, CCR5 DRD2 349/4885DRD3 165/4885KCNH2 2018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.